Table 1.

Clinicopathologic features of BRAF alterations in high-grade colorectal NETs

CaseAgeSexTumor locationStage, gradeKRAS, APC statusBRAF eventTumor purity (%)BRAF MAF (%)BRAF coverageSample coverageResponse to BRAF-i
1*70FRectumIV, 3KRAS: WTV600E5926463529Yes
APC: WT
239FRectumIV, 3KRAS: WTV600E4953734647Yes
APC: WT
364MRectumIV, 3KRAS: WTG469A80551,446904N/A
APC: R1114*
APC: V1414fs*1
466MColonIV, 2KRAS: G12SV600E361402459N/A
APC: WT
551FColonIV, 3KRAS: WTV600E3031372445N/A
APC: R554*
APC: Q1541*
662MColonIV, 3KRAS: WTV600E78541,079596N/A
APC: WT
778MRectumIV, 3KRAS: WTV600E6034612430N/A
APC: WT
845FColonIV, 3KRAS: WTV600E6642587436N/A
APC: WT
970MColonIV, 2KRAS: A146TR671Q3044636612N/A
APC: R1450*
1069FRectumIV, 3KRAS: WTV600E199552575N/A
APC: WT
  • Abbreviations: BRAF-i, BRAF inhibitor; F, female; M, male; WT, wild-type; N/A, data not available. Asterisk (*) represents the incident case, case 1.